Clinical trials: NAFLD Cirrhosis
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.
- Trial name
- STELLAR-4 (NCT03053063)
- Testing
- SEL
- Where
- 283 sites in United States, Australia and 20 more
- Volunteers
- 883 people
- Sponsor
- Gilead Sciences
Liver Diseases, Alcoholic, Fibrosis
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients…
- Trial name
- SIPHON (NCT03308916)
- Testing
- transient elastography, Enhanced liver fibrosis test, Indirect serum markers of liver fibrosis
- Where
- Denmark
- Volunteers
- 6,500 people
- Sponsor
- Maja Thiele
Non-alcoholic Fatty Liver Disease
Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a condition where accumulation of fat in the liver leads to metabolic dysfunction. Currently there are no approved treatments for NAFLD.
- Trial name
- NCT02568605
- Testing
- Prebiotic fibre, Weight Loss
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Calgary
NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
This is an open-label, randomized study comparing a monitored ketogenic diet intervention using standard ketogenic diet (SKD) and standard of care (SOC) dietary recommendations for 16 weeks.
- Trial name
- NCT04383951
- Testing
- Dietary consult for participants in the ketogenic diet arm, Dietary consult for participants in the standard of care arm
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver Fibrosis
- Trial name
- NCT07827430
- Volunteers
- 120 people
- Sponsor
- Assiut University
Non-alcoholic Steatohepatitis
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis
This study aims at evaluating and comparing the protective outcomes of using Obeticholic acid versus Vitamin E in NASH patients without cirrhosis.
- Trial name
- NCT05573204
- Testing
- Obeticholic Acid Oral Tablet, Vit E
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Tanta University
Safety and Tolerability
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult…
- Trial name
- NCT03809052
- Testing
- GB1211
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Liver Fibrosis, Liver Cirrhosis
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness
Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease.
- Conditions
- Liver Fibrosis, Liver Cirrhosis, NAFLD (Nonalcoholic Fatty Liver Disease), HEPATITIS B CHRONIC
- Trial name
- NCT07716384
- Testing
- Wearable Patch-Type Ultrasound Probe, Transient Elastography (FibroScan)
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Chronic Liver Disease, Fibrosis, Liver
Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity
The aims of this study are to assess the performance of the non-invasive Electrical Impedance Technology (EIT) in evaluating the liver fibrosis stage in patients with chronic liver diseases, in comparisons with a liver biopsy…
- Conditions
- Chronic Liver Disease, Fibrosis, Liver, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03492879
- Testing
- EIT Technology
- Volunteers
- 210 people
- Sponsor
- Prof. Ziv Ben-Ari MD
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT07553663
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corcept Therapeutics
Moderate Liver Impairment, Severe Liver Impairment
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment.
- Trial name
- NCT04634149
- Testing
- BMS-986036
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Nonalcoholic Steatohepatitis
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis…
- Trial name
- WAYFIND (NCT04971785)
- Testing
- Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA
- Where
- 242 sites in United States, Australia and 5 more
- Volunteers
- 457 people
- Sponsor
- Gilead Sciences
Morbid Obesity, Diabetes
Bariatric Surgery and Fatty Liver Disease
The study is based on data from morbidly obese patients who fulfilled the criteria for bariatric surgery during 2016-2018 at the Department of Surgery, University Hospital Ostrava, Czech Republic.
- Conditions
- Morbid Obesity, Diabetes, Hypertension
- Trial name
- NCT04569396
- Testing
- Biochemistry analysis, NAFLD fibrosis score, BMI measurement
- Where
- Czechia
- Volunteers
- 72 people
- Sponsor
- University Hospital Ostrava
ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
- Trial name
- DISTEMI (NCT05046483)
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- German Diabetes Center
Nonalcoholic Steatohepatitis
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are: To assess the safety and tolerability of selonsertib (SEL), firsocostat (FIR) and cilofexor (CILO), administered alone or in combination, in participants with bridging fibrosis or…
- Trial name
- ATLAS (NCT03449446)
- Testing
- SEL, FIR, CILO
- Where
- 101 sites in United States, Australia and 4 more
- Volunteers
- 395 people
- Sponsor
- Gilead Sciences
Non-alcoholic Fatty Liver Disease, Liver Fibrosis
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease globally, with an estimated prevalence of approximately 15 to 30%.
- Conditions
- Non-alcoholic Fatty Liver Disease, Liver Fibrosis, Liver Injury
- Trial name
- NCT06244550
- Testing
- Ganwei, Metformin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei City Hospital
NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease )
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth…
- Conditions
- NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis
- Trial name
- COMET cohort (NCT07241195)
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
NAFLD, Hepatocellular Carcinoma
Utilization of MAsS in Patients Undergoing LT for HCC
The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
- Conditions
- NAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer
- Trial name
- NCT05184283
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
NASH, NAFLD
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans.
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash
- Trial name
- CODIN (NCT06588699)
- Testing
- Digoxin
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Yale University